Hoffmann K J, Renberg L, Gyllenhaal O
AB Hässle Cardiovascular Research Laboratories, Mölndal, Sweden.
Biopharm Drug Dispos. 1990 May-Jun;11(4):351-63. doi: 10.1002/bdd.2510110404.
The potential of stereoselective metabolism of tocainide was studied in six healthy volunteers after separate oral administration of the pure enantiomers in solution. A method was developed to convert the N-carbamoylglucuronide of tocainide in plasma and urine by base treatment to a hydantoin derivative which after extraction and silation was analysed by selected ion monitoring using a deuterated internal standard. Analytical problems concerning side-reactions during derivatization of the conjugate are discussed. The peak plasma levels of the enantiomers, observed at less than or equal to 2 h after dosing, were similar but plasma clearances and terminal half-lives were different after oral administration of (R)-tocainide (195.5 +/- 20.1 ml min-1 and 9.7 +/- 0.8 h) and (S)-tocainide (110.2 +/- 10.5 ml min-1 and 14.5 +/- 1.7 h). Over 0-96 h the averaged urinary recovery of (R)-tocainide was 36 per cent and of (S)-tocainide 50 per cent. Stereoselective metabolism was a likely mechanism for the observed differences as the urinary recovery of the conjugate formed from (R)-tocainide differed substantially from that of (S)-tocainide (45 vs 1.2 per cent of given dose). Plasma t1/2 of the (R)- and (S)-conjugate were 9.9 and 18.7 h, respectively, indicating formation rate limited kinetics of the metabolite. The renal clearances of the conjugates were not significantly different (131 vs 97 ml min-1).
在六名健康志愿者分别口服溶液中的纯对映体后,研究了妥卡尼立体选择性代谢的潜力。开发了一种方法,通过碱处理将血浆和尿液中妥卡尼的N-氨基甲酰葡萄糖醛酸转化为乙内酰脲衍生物,提取和硅烷化后,使用氘代内标通过选择离子监测进行分析。讨论了共轭物衍生化过程中副反应的分析问题。给药后不到或等于2小时观察到的对映体血浆峰值水平相似,但口服(R)-妥卡尼(195.5±20.1 ml min-1和9.7±0.8小时)和(S)-妥卡尼(110.2±10.5 ml min-1和14.5±1.7小时)后血浆清除率和终末半衰期不同。在0-96小时内,(R)-妥卡尼的平均尿回收率为36%,(S)-妥卡尼为50%。立体选择性代谢可能是观察到差异的机制,因为由(R)-妥卡尼形成的共轭物的尿回收率与(S)-妥卡尼的尿回收率有很大差异(给药剂量的45%对1.2%)。(R)-和(S)-共轭物的血浆t1/2分别为9.9和18.7小时,表明代谢产物的形成速率限制了动力学。共轭物的肾清除率无显著差异(131对97 ml min-1)。